# A novel agent targeting APRIL: A new hope for elderly patients of IgA nephropathy

**Authors:** Xin Liu, Li Zuo

PMC · DOI: 10.1002/agm2.12370 · Aging Medicine · 2025-01-20

## TL;DR

This paper introduces a new treatment, sibeprenlimab, that targets APRIL and offers hope for elderly patients with IgA nephropathy.

## Contribution

The novelty lies in the development of sibeprenlimab, a humanized monoclonal antibody targeting APRIL for IgAN treatment.

## Key findings

- Sibeprenlimab neutralizes APRIL activity, which is crucial in IgA nephropathy.
- The treatment is expected to be particularly effective for elderly IgAN patients.

## Abstract

Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes the activity of APRIL. It should usher in a new era in the treatment of IgAN, especially in elderly patients.

## Linked entities

- **Proteins:** TNFSF13 (TNF superfamily member 13)
- **Diseases:** IgA nephropathy (MONDO:0005342)

## Full-text entities

- **Diseases:** IgA nephropathy (MESH:D005922)
- **Chemicals:** Sibeprenlimab (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11817024/full.md

## References

16 references — full list in the complete paper: https://tomesphere.com/paper/PMC11817024/full.md

---
Source: https://tomesphere.com/paper/PMC11817024